Kiniksa Pharmaceuticals International, plcKNSA

時価総額

$61.5億

PER

希少疾患向けバイオ医薬品の新興企業。ARCALYSTやvixarelimab、KPL-387などの候補薬を展開。2016年9月に外部企業からvixarelimab関連資産を買収し11,500千ドル支払い。米国・欧州・中国で展開。

	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net income (loss)	-103	-162	-161	-158	183	14	-43
Depreciation and amortization expense	-	-	-	2	2	2	2
Share-based compensation expense	6	15	21	25	25	27	31
Noncash Lease Expense	-	1	1	3	3	3	3
Amortization (accretion) of discounts on short-term investments	1	4	-0	-1	0	1	-0
Gain on disposal of property and equipment	-	-	-	-	-	-	0
Loss on disposal of property and equipment	-0	-0	-	-0	-0	-0	-0
Deferred income taxes	-1	-3	4	0	-185	-34	8
Prepaid expenses and other current assets	5	1	1	-3	4	7	3
Accounts receivable, net	-	-	-	4	9	9	20
Inventory	-	-	-	4	18	10	-5
Contract asset	-	-	-	-	8	-8	-
Other long-term assets	-	-	6	3	-3	-5	10
Accounts payable	9	-5	-5	1	6	0	-6
Increase (Decrease) in Accrued Liabilities	9	5	9	10	-4	17	44
Operating lease liabilities	-	-1	-2	-3	-3	-3	-4
Deferred revenue	-	-	-	-	12	0	20
Other long-term liabilities	-	0	0	-1	2	0	-0
Net cash provided by operating activities	-81	-158	-137	-126	6	13	26
Proceeds from sale of property and equipment	-	-	-	-	0	-	0
Purchases of property and equipment	5	3	0	0	0	0	0
Purchases of short-term investments	402	489	430	157	136	205	202
Proceeds from the maturities of short-term investments	168	541	407	306	128	176	240
Net cash provided by (used in) investing activities	-239	49	-23	129	-8	-30	38
Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised	-	-	-	6	3	4	17
Payments in connection with ordinary stock tendered for employee tax obligations	-	-	-	-	1	2	5
Net cash provided by financing activities	347	84	227	6	3	1	12
Net increase (decrease) in cash and cash equivalents	27	-25	67	8	0	-15	76
Income Taxes Paid, Net	-	-	-	1	11	6	2
Change In Right Of Use Asset, New, Modified, and Terminated Leases	-	-	-	-	-	10	2
Capital Expenditures Incurred but Not yet Paid	1	0	-	-	-	0	0